Navigation Links
2009 Science Report on Genetic Disease Released by Cystinosis Research Foundation
Date:3/9/2009

Researchers of the genetic disease Cystinosis report encouraging news. The Cystinosis Research Foundation has published the third edition of its Science Report, which is designed to provide updates on cystinosis research under way and includes new abstracts of the 12 cystinosis grants issued in 2008. Cystinosis is a rare and fatal metabolic genetic disease that afflicts about 2,000 children worldwide. The CRF Science Report is available at www.cystinosisresearch.org

Irvine, CA (PRWEB) March 9, 2009 -- Researchers of the genetic disease Cystinosis report encouraging news. The Cystinosis Research Foundation has published the third edition of its Science Report, which is designed to provide updates on cystinosis research under way and includes new abstracts of the 12 cystinosis grants issued in 2008. Cystinosis is a rare, genetic and slowly fatal metabolic disease that afflicts about 2,000 children worldwide. The CRF Science Report is available at www.cystinosisresearch.org.

The CRF research teams working on a cure for cystinosis continue to report encouraging news. The research undertaken has "significantly changed the course of cystinosis research and we are moving closer to our mission: to find improved cystinosis treatments and a cure for cystinosis," said Nancy Stack, president of CRF.

The Cystinosis Research Foundation was formed in 2003 and has raised $9.3 million, all of which is committed for medical research. The CRF is the largest fund provider of cystinosis research in the world. Currently, the CRF is funding 25 cystinosis research studies, including seven research fellows in six countries. The foundation has $1.2 million available for new research and plans to issue a global call for research proposals and fellowship grants on March 15, 2009. In 2008, the CRF funded 12 studies with grants totaling $1,741,889.

"The advancements achieved so far are the result of the CRF's focused mission and targeted approaches to cystinosis research. This gets research funds directly into the labs of the world's leading cystinosis doctors and scientists so they can complete their important work. This policy has produced a greater understanding of the disease and the first improvement in treatment to come in more than 25 years," she said.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of the cell. This causes development of crystals, resulting in early cell death.

The genetic disease slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children's lives, but there is no cure. Almost all sufferers succumb before 40 years old.

Today, with the support of CRF's friends and community the foundation has significantly changed the course of cystinosis research and this genetic disease. CRF's funding efforts have allowed talented doctors and leading cystinosis researchers into initiate novel research studies and advance their cystinosis research efforts. For more information on the organization and its science report call CRF at 949-22-7610 or visit the site.

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2208574.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Americans United for Life: Rescinding of Conscience Protections for Healthcare Providers Outrageous
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
3. New Book Exposes Junk Science, Conflicts of Interest, Disease Guidelines Affecting Millions
4. HIV Experts Propose New Approach to Eradicate HIV in Latest Issue of Science
5. Daisyphone, virtual cocoon and smart house at London science conference
6. Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium
7. Sigma-tau HealthScience Launches www.GlycoCarn.com
8. SpectraScience Receives FDA Clearance for Manufacturing Facility
9. Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call
10. Bishops Pro-Life Official Gravely Concerned Over Threat to HHS Conscience Protection Regulation
11. Bill Would Require Nutrition Info on Chain Restaurant Menus and Menu Boards, Says Center for Science in the Public Interest -- News Conference on Tuesday, March 3 in Annapolis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Massachusetts (PRWEB) , ... February 10, 2016 , ... ... models to effectively measure change in their patients. Research shows that the Goal ... methods. To help therapists overcome this challenge and learn more about the Goal ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... has been awarded the prestigious Distinguished Emerald Club of the World award, as ... BoardRoom magazine, one of the most respected trade publications serving private clubs. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has ... state still face a lot of restrictions as to where they can smoke pot. ... personal use” and that cannabis “may not be consumed openly or publicly.” , Given ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: